2상모집 중단 (진행 중)

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

연구 개요

This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2-expressing solid tumors which are not eligible for curative therapy.

스폰서: 리드: 아스트라제네카
적응증: Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
중재: Trastuzumab deruxtecan, Bevacizumab
목표 등록: 127명
시작일: 2024-02-22
완료(예정): 2027-02-10
등록번호: NCT06271837 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.